
Research Peptide Blend
MISSION CRITICAL: For in vitro laboratory research only. Not for human or veterinary use. Not evaluated by the FDA. Must be 21+.
BPC/TB500 is a research blend combining BPC-157 (Body Protection Compound-157, CAS: 137525-51-0) and TB-500 (Thymosin Beta-4 fragment, CAS: 885340-08-9), two cytoprotective peptides studied independently in preclinical tissue models for their respective interactions with the nitric oxide system and actin cytoskeleton dynamics. The blend formulation is supplied at ≥99% HPLC purity as a lyophilized powder for laboratory research use only.
BPC-157 component modulates nitric oxide synthase expression and activity in vascular tissue models (PMID: 35489163).
TB-500 component binds monomeric G-actin, regulating cytoskeletal dynamics in cell culture models (PMID: 15283699).
Sikiric et al. (2022) investigated BPC-157's interactions with growth factor and cytokine signaling pathways in gastric tissue models (PMID: 35489163).
Sikiric P, et al. (2022). BPC-157 and its healing effects. Front Pharmacol.PMID: 15283699Malinda et al. (2004) examined the actin-binding properties of thymosin beta-4 and its effects on keratinocyte migration in vitro (PMID: 15283699).
Malinda KM, et al. (2004). Thymosin beta4 accelerates wound healing. J Invest Dermatol.